Entanglement potentials are a promising way to quantify the nonclassicality of single-mode states. They are defined by the amount of entanglement (expressed by, e.g., the Wootters concurrence) obtained after mixing the examined single-mode state with a purely classical state; such as the vacuum or a coherent state. We generalize the idea of entanglement potentials to other quantum correlations: the EPR steering and Bell nonlocality, thus enabling us to study mutual hierarchies of these nonclassicality potentials. Instead of the usual vacuum and one-photon superposition states, we experimentally test this concept using specially tailored polarization-encoded single-photon states. One polarization encodes a given nonclassical single-mode state, while the other serves as the vacuum place-holder. This technique proves to be experimentally more convenient in comparison to the vacuum and a one-photon superposition as it does not require the vacuum detection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/OE.506169 | DOI Listing |
Lancet
January 2025
Executive Committee, Regionalized Vaccine Manufacturing Collaborative (RVMC), Oslo, Norway.
Aliment Pharmacol Ther
February 2025
Division of Gastroenterology and Hepatology, University of Kansas School of Medicine, and Kansas City VA Medical Center, Kansas City, Missouri, USA.
Background: Many patients diagnosed with gastro-oesophageal reflux disease (GERD) have persistent symptoms despite proton pump inhibitor (PPI) therapy.
Aims: The aim of this consensus is to provide evidence-based statements to guide clinicians caring for patients with refractory reflux-like symptoms (rRLS) or refractory GERD.
Methods: This consensus was developed by the International Working Group for the Classification of Oesophagitis.
Radiology
December 2024
From the Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, Calif (M.S.S., S.C., Z.F., N.A., S.N.); Department of Radiology, Mayo Clinic, Rochester, Minn (B.J.E.); Department of Radiology, Mayo Clinic, Scottsdale, Ariz (L.S.H., Y.Z.); Division of Neuroradiology, Department of Radiology, Duke University School of Medicine, Durham, NC (D.P.B.); Invicro, Needham, Mass (L.B.); Clinical Imaging Group, Genentech, South San Francisco, Calif (L.C.B.); Imaging Core Laboratory, American College of Radiology, Philadelphia, Pa (M.A.B., L.C.); Section of Neuroradiology, Department of Diagnostic Imaging, Warren Alpert Medical School of Brown University, Providence, RI (J.L.B.); National Institute of Standards and Technology, Boulder, Colo (K.E.K.); Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 13th St, CNY 2301, Charlestown, MA 02129 (J.E.K., L.R., O.W.); Barrows Neurologic Institute, Phoenix, Ariz (C.C.Q.); Cancer Systems Imaging, MD Anderson Cancer Center, Houston, Tex (C.C.Q.); Department of Radiology, Division of Abdominal Imaging, Hospital of the University of Pennsylvania, Philadelphia, Pa (M.A.R.); College of Undergraduate Studies, University of Central Florida, Orlando, Fla (L.R.); Department of Biophysics, Medical College of Wisconsin, Milwaukee, Wis (K.M.S.); Independent Consultant, Basel, Switzerland (G.Z.); and Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio (N.O.).
The dynamic susceptibility contrast (DSC) MRI measures of relative cerebral blood volume (rCBV) play a central role in monitoring therapeutic response and disease progression in patients with gliomas. Previous investigations have demonstrated promise of using rCBV in classifying tumor grade, elucidating tumor viability after therapy, and differentiating pseudoprogression and pseudoresponse. However, the quantification and reproducibility of rCBV measurements across patients, devices, and software remain a critical barrier to routine or clinical trial use of longitudinal DSC MRI in patients with gliomas.
View Article and Find Full Text PDFBackground: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides a comprehensive assessment of health and risk factor trends at global, regional, national, and subnational levels. This study aims to examine the burden of diseases, injuries, and risk factors in the USA and highlight the disparities in health outcomes across different states.
Methods: GBD 2021 analysed trends in mortality, morbidity, and disability for 371 diseases and injuries and 88 risk factors in the USA between 1990 and 2021.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!